Multiple sclerosis (MS) affects predominantly women (~3:1) and has a mean age of onset of approximately 30 years. Thus, many of those affected will be women in their child-bearing years. In this era, in which many options for disease-modifying therapy (DMT) for relapsing forms of MS are available, the question often arises about the use of DMTs while a woman attempts to conceive and, indeed, in some instances during pregnancy itself.
Women (and their partners) often express concern about their risk of having a relapse if they discontinue medication to try to get pregnant, as well as the impact of the pregnancy itself on that risk. Pregnancy does offer some protection against relapses, but studies indicate that the relapse rate only declines substantially in the third trimester. Two large studies each showed the same shape of the relapse curve, albeit with different relapse rates. In one study, Vukusic et al. 1 reported a relapse rate of 0.7 in the year prepartum, falling to 0.5 in the first trimester, 0.6 in the second trimester, and 0.2 in the third trimester, but rising to 1.2 in the first 3 months post-partum. In another study, Hughes et al. 2 reported annualized relapse rates of 0.32 in the 2 years pre-partum, compared with 0.25 in the first trimester of pregnancy and 0.13 in the third trimester. The rate then rose to 0.61 in the first 3 months post-partum.
A potentially more significant problem occurs during the period in which the woman is attempting to become pregnant. Overall, data indicate that 30% of women will become pregnant within 1 month of beginning to try, 60% within 3 months, 80% within 6 months, and 85% within a year. 3 However, the success rate drops significantly for women over the age of 35 and, with an average age of onset of MS at about 30, many women with MS who are considering pregnancy will be in the older age range. In the recent Hughes study of 893 pregnancies, 2 discontinuation of DMT occurred a median of 7.1 months before the onset of pregnancy. Furthermore, high rates of successful conception such as those cited above are based on frequent, regular sexual intercourse (two to three times per week) throughout the period in which the woman is attempting to become pregnant. However, studies have also shown that 40%-80% of women with MS report diminished sexual activity for a variety of reasons. 4 Based on this information, it is likely that a substantial number of women would be deprived of the benefit of DMTs for a period of many months if they come off medication to become pregnant.
In this issue of Multiple Sclerosis Journal, Thiel et al. 5 and Herbstritt et al., 6 using data collected from a large German pregnancy registry, have provided convincing evidence that it is safe for women to remain on either an interferon beta (IFNB) preparation or glatiramer acetate (GA), respectively, at least until pregnancy is confirmed. There has never been much reason to fear a teratogenic effect of interferon. However, because experimental animal studies showed an increased rate of spontaneous abortion, many clinicians have recommended that women discontinue IFNB at least 1-2 months prior to attempting conception. The Thiel study adds substantially to previous information (cited by the authors) that fails to support an increased spontaneous abortion rate in humans taking interferon, at least early in pregnancy. In addition, for both interferon and GA, no negative impact was found on birth weight or gestational age.
Previously available, albeit limited, information has suggested that, indeed, GA may be safe for a woman to take even throughout pregnancy, thereby maintaining its effect in the vulnerable post-partum period. This author has reported that when offered a choice, most women have elected to remain on GA at least until pregnant and a substantial majority of these have chosen to continue the medication throughout the pregnancy, with no significant consequences in terms of birth defects. 7 While the reports from Thiel et al. and Herbstritt et al. support the practice of a woman's continuing on either IFNB or GA at least until she knows she is pregnant, the important question remains about what to recommend for a woman who is taking an oral medication or natalizumab. Fingolimod, teriflunomide, and dimethyl fumarate, the oral agents available in the United States, much of Western Europe, and many other countries, are all small molecules, which almost certainly cross the placental barrier. Each of these agents has been shown to have teratogenic effects in experimental animals 8-10 and should not be taken by women who are pregnant or attempting to conceive. Indeed, because of its very slow exodus from the body, women taking teriflunomide are advised to undergo an accelerated elimination protocol before trying to become pregnant. 9 What, then, should a woman who is taking one of these newer DMTs do if she wants to become pregnant? Ideally, a reproductive counseling session should be conducted with the woman and, hopefully, also with her partner, well in advance of attempts at conception. Then, of course, planning the pregnancy is the preferred course of action and the woman can make a decision about the use of DMTs in advance of trying to conceive. One option is simply to discontinue the oral DMT and hope that pregnancy rapidly ensues. Another possibility, especially in light of the data published in this issue, is for a woman to switch from the oral medication to either IFNB or GA prior to beginning her attempt to become pregnant. If this course of action is selected, one must be aware of the early studies that suggested that GA may take 6-9 months to become fully effective, 11 although this observation was called into question by the results of the REGARD trial, which showed no difference in the time to first relapse between IFNB-1a subcutaneously three times a week and GA. 12 A woman who is considering pregnancy ideally should be counseled about many issues, preferably as early as possible. Matters for discussion should include genetic risks for the offspring, expected obstetrical management (usually no different than that for unaffected women), impact of MS on pregnancy outcome (little or none), effect of pregnancy and nursing on the course of MS, the use of medication, and, occasionally, issues related to assisted reproductive technology. 13 Finally, in some instances, frank discussion about the impact of the MS on the woman's physical ability to care for a child or to economically provide for the child is appropriate. In the final analysis, the vast majority of women with MS will be able to conceive, will deliver healthy babies, and will experience little or no impact on the long-term course of their MS.
